Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1

Int J Impot Res. 1996 Jun;8(2):41-6.


We report in this retrospective study the results obtained with the first two drugs proposed to reduce the relatively high rates of priapism and fibrosis bound to the papaverine intracavernous injections, i.e. the alpha-blocking agent Moxisylyte (Mox), and prostaglandin E1 (PGE1). Each drug was used for auto-injections in 130 patients with a comparable mean follow up (14.8 months with Mox compared to 14.6 with PGE1). PGE1 proved to be significantly more efficacious (good results in 71% of the patients vs 50% with Mox), especially in the arteriogenic patients (respectively 96% vs 46%). Conversely PGE1 induced prolonged erections in significantly more patients (11 vs 1 with Mox), including 2 priapisms, and also induced pain in more patients (12 vs 1 with Mox). The rate of fibrotic nodules and plaques was low (2 and 3 patients). Despite the better tolerance of Mox, its continuation rate was significantly lower than that of PGE1, PGE1 can be the first choice agent in most cases. Mox is mainly indicated in the patients with supersensitivity to the injections and in those with significant pain following PGE1.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Alprostadil / adverse effects*
  • Alprostadil / therapeutic use
  • Dose-Response Relationship, Drug
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / etiology
  • Erectile Dysfunction / psychology
  • Fibrosis
  • Humans
  • Impotence, Vasculogenic / drug therapy
  • Injections
  • Male
  • Middle Aged
  • Moxisylyte / administration & dosage*
  • Moxisylyte / adverse effects
  • Moxisylyte / therapeutic use
  • Penis / pathology
  • Priapism / chemically induced
  • Retrospective Studies
  • Vasodilator Agents / administration & dosage*
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / therapeutic use


  • Vasodilator Agents
  • Alprostadil
  • Moxisylyte